BioLineRx Ltd.

2.93
-0.17 (-5.48%)
At close: Apr 03, 2025, 12:30 PM
-5.48%
Bid 2.91
Market Cap 10.9M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -6
PE Ratio (ttm) -0.49
Forward PE -0.99
Analyst Buy
Ask 2.96
Volume 11,715
Avg. Volume (20D) 180,507
Open 2.98
Previous Close 3.10
Day's Range 2.91 - 2.99
52-Week Range 2.85 - 35.60
Beta 1.30

About BLRX

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in pat...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 27, 2011
Employees 79
Stock Exchange NASDAQ
Ticker Symbol BLRX
Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for BLRX stock is "Buy." The 12-month stock price forecast is $26, which is an increase of 787.37% from the latest price.

Stock Forecasts

Earnings Surprise

BioLineRx Ltd. has released their quartely earnings on Mar 31, 2025:
  • Revenue of $11.75M exceeds estimates by $4.03M, with 144.77% YoY growth.
  • EPS of 0 misses estimates by 0.00, with 100.00% YoY growth.
  • Next Earnings Release

    BioLineRx Ltd. is scheduled to release its earnings on May 27, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 months ago
    -16.8%
    BioLineRx shares are trading lower after the compa... Unlock content with Pro Subscription
    2 months ago
    -40.82%
    BioLineRx shares are trading lower after the company announced a $10 million registered direct offering.